AI assistant
INOVIQ LTD — Capital/Financing Update 2018
Dec 11, 2018
65112_rns_2018-12-11_566b1bf8-926e-4463-894c-a5199ad72efe.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [155 x 50] intentionally omitted <==
CLOSURE OF ENTITLEMENT OFFER AND NOTIFICATION OF SHORTFALL
Perth, Australia, 12 December 2018: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) ( BARD1 LSL or the Company ) is pleased to announce that the non-renounceable Entitlement Offer ( Offer ) to raise approximately $3.3 million (before costs) closed at 2:00pm (WST) on Monday, 10 December 2018 as per the terms of the Offer.
The Company has received applications to subscribe for 59,141,273 new Shares from eligible shareholders under the Offer raising $1,184,484.26.
All new shares issued under the Entitlement Issue will rank equally in all respects with the existing fully paid ordinary shares of the Company.
As outlined in the Offer Document the Company entered into a mandate letter ( Mandate ) with Merchant Corporate Advisory Pty Ltd ( Merchant ) who have agreed under the Mandate to subscribe for and/or place all Shortfall Shares under the Offer.
- ENDS -
FOR MORE INFORMATION PLEASE CONTACT:
| Peter Gunzburg | Dr Leearne Hinch |
|---|---|
| Chairman | CEO |
| E [email protected] | E [email protected] |
| M+61 400 414 416 |
ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. Its lead product, the BARD1 Lung Cancer Test, is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm. The company’s pipeline also includes the BARD1 Ovarian Cancer Test in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research-stage for multiple cancers. BARD1 LSL is committed to transforming the early detection and prevention of cancer to help improve patients' lives.
BARD1 Life Sciences Limited (ABN 58 009 070 384) Headquarters | Harry Perkins Institute, L2/QQ Block, 6 Verdun St, Nedlands WA 6009, Australia Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E [email protected] | W www.bard1.com